Cefazolin


Thông tin thuốc gốc
Chỉ định và Liều dùng
Intramuscular, Intravenous
Biliary tract infections, Bone and joint infections, Endocarditis, Genitourinary infections, Respiratory tract infections, Septicaemia, Skin and soft tissue infections
Adult: Mild cases: 250-500 mg 8 hourly. Moderate to severe cases: 500-1,000 mg 6-8 hourly. Severe, life-threatening cases: 1,000-1,500 mg 6 hourly. Max: 12,000 mg daily. Doses are given via deep IM inj, slow IV inj over 3-5 minutes, or intermittent or continuous IV infusion. Dosage and treatment recommendations may vary among countries and individual products (refer to specific product guidelines).
Child: >1 month Mild to moderately severe cases: 25-50 mg/kg daily in 3 or 4 divided doses. Severe cases: Up to 100 mg/kg daily may be given in 3 or 4 divided doses. Doses are given via deep IM inj, slow IV inj over 3-5 minutes, or intermittent or continuous IV infusion. Dosage and treatment recommendations may vary among countries and individual products (refer to specific product guidelines).

Intramuscular, Intravenous
Acute uncomplicated urinary tract infections
Adult: 1,000 mg 12 hourly to be given via deep IM inj, slow IV inj over 3-5 minutes, or intermittent or continuous IV infusion. Max: 12,000 mg daily. Dosage and treatment recommendations may vary among countries and individual products (refer to specific product guidelines).

Intramuscular, Intravenous
Prophylaxis of surgical infections
Adult: Peri-operative dose: 1,000 mg given 30-60 minutes prior to surgery. For long surgeries (≥2 hours): Additional doses of 500-1,000 mg may be given during the surgery. Post-operative doses: 500-1,000 mg 6-8 hourly for 24 hours. Doses are given via deep IM inj, slow IV inj over 3-5 minutes, or intermittent or continuous IV infusion. Dosage and treatment recommendations may vary among countries and individual products (refer to specific product guidelines).

Intramuscular, Intravenous
Pneumonia
Adult: 500 mg 12 hourly to be given via deep IM inj, slow IV inj over 3-5 minutes, or intermittent or continuous IV infusion. Max: 12,000 mg daily. Dosage and treatment recommendations may vary among countries and individual products (refer to specific product guidelines).

Suy thận
Adult:
Dosage recommendations apply after an initial loading dose is administered.
CrCl (mL/min) Dosage
≤10 Half the usual dose 18-24 hourly.
11-34 Half the usual dose 12 hourly.
35-54 Usual dose 8 hourly.

Respiratory tract infections; Genitourinary infections; Skin and soft tissue infections; Biliary tract infections; Bone and joint infections; Septicaemia; Endocarditis:
Child:
Dosage recommendations apply after an initial loading dose is administered.
CrCl (mL/min) Dosage
5-20 10% of the normal daily dose 24 hourly.
20-40 25% of the normal daily dose in 2 divided doses.
40-70 60% of the normal daily dose in 2 divided doses.
Hướng dẫn pha thuốc
Add 2 mL, 2.5 mL, or 5 mL of sterile water for inj to the vial labelled as 500 mg, 1 g, or 2 g respectively, to provide a solution containing approx 225 mg/mL, 330 mg/mL or 333 mg/mL. Further dilute the reconstituted solution in approx 10 mL of sterile water for inj to be used for IV inj or in 50-100 mL of compatible IV solution for IV infusion. Instructions for reconstitution may vary among countries and individual products. Refer to specific product guidelines.
Tương kỵ
Incompatible with ascorbic acid, amikacin disulfate, amobarbital Na, bleomycin sulfate, Ca gluceptate, Ca gluconate, cimetidine hydrochloride, colistimethate Na, erythromycin gluceptate, kanamycin sulfate, oxytetracycline hydrochloride, pentobarbital Na, polymyxin B sulfate, and tetracycline hydrochloride.
Chống chỉ định
Hypersensitivity to cefazolin, other cephalosporin antibiotics, or any other β-lactam antibiotic (e.g. penicillin, monobactam, carbapenem).
Thận trọng
Patients with history of gastrointestinal disease (e.g. colitis), seizure disorder, allergic reactivity (e.g. allergic rhinitis, bronchial asthma). Patients with poor nutritional state. Renal impairment. Neonates and children. Pregnancy and lactation.
Tác dụng không mong muốn
Significant: Increased INR, prolonged prothrombin time; bacterial or fungal superinfection; seizures (high doses in patients with renal impairment).
Gastrointestinal disorders: Loss of appetite, diarrhoea, nausea, vomiting.
General disorders and administration site conditions: Pain at the site of IM inj, induration; thrombophlebitis (IV).
Immune system disorders: Erythema multiforme, angioedema, drug-induced fever and interstitial pneumonia or pneumonitis.
Infections and infestations: Oral candidiasis (prolonged use).
Skin and subcutaneous tissue disorders: Rash.
Potentially Fatal: Hypersensitivity reactions, Clostridioides difficile-associated diarrhoea, pseudomembranous colitis.
IM/Intraocular/Intraperitoneal/IV/Parenteral: B
Chỉ số theo dõi
Perform culture and susceptibility tests; consult local institutional recommendations before treatment initiation due to antibiotic resistance risks. Evaluate the patient's allergy history before treatment initiation. Monitor renal function, LFTs, and CBC. Assess for signs of anaphylaxis during 1st dose.
Quá liều
Symptoms: Pain, inflammation, and phlebitis at the inj site; seizures, dizziness, paraesthesia, and headache. Management: Symptomatic and supportive treatment. If seizures occur, discontinue treatment; administer anticonvulsant if clinically indicated. Protect the patient's airway and support ventilation and perfusion. Monitor and maintain the patient's vital signs, blood gases and serum electrolytes within acceptable limits.
Tương tác
Increased and prolonged plasma concentration with probenecid. Increased nephrotoxic effects of aminoglycosides, colistin, polymyxin B, iodine-containing contrast agents, organoplatinum compounds, high dose methotrexate, certain antivirals, pentamidine, ciclosporin, tacrolimus and diuretics. May enhance the therapeutic effect of anticoagulants. May diminish the therapeutic effect of typhoid vaccine.
Tương tác với thức ăn
May cause a disulfiram-like reaction with alcohol.
Ảnh hưởng đến kết quả xét nghiệm
Positive direct and indirect Coombs' test. False-positive results on urinary glucose tests based on Benedict's copper reduction reaction or Fehling's solution. False-positive results for tests on urine creatinine with Jaffe reaction.
Tác dụng
Description:
Mechanism of Action: Cefazolin, a 1st-generation cephalosporin, is an antibiotic. It inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls by binding to 1 or more of the penicillin-binding proteins, thereby inhibiting cell wall biosynthesis and causing eventual bacterial lysis.
Pharmacokinetics:
Absorption: Time to peak plasma concentration: 0.5-2 hours (IM); within 5 minutes (IV).
Distribution: Widely distributed into most body tissues and fluids, including gallbladder, liver, kidneys, bone, sputum, bile, pleural, and synovial; CSF (low concentrations). Crosses the placenta; enters breast milk (low concentrations). Plasma protein binding: Approx 70-90%.
Excretion: Via urine (70-80% as unchanged drug). Elimination half-life: Approx 2 hours (IM); approx 1.8 hours (IV).
Đặc tính

Chemical Structure Image
Cefazolin

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 33255, Cefazolin. https://pubchem.ncbi.nlm.nih.gov/compound/Cefazolin. Accessed Aug. 14, 2023.

Bảo quản
Store between 15-30°C. Protect from light.
Phân loại MIMS
Cephalosporin
Phân loại ATC
J01DB04 - cefazolin ; Belongs to the class of first-generation cephalosporins. Used in the systemic treatment of infections.
Tài liệu tham khảo
Committee on Infectious Diseases, American Academy of Pediatrics, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH. "Tables of Antibacterial Drug Dosages", Red Book: 2021-2024 Report of the Committee on Infectious Diseases. American Academy of Pediatrics [online]. Accessed 12/04/2023.

AFT Pharmaceuticals Ltd. Cefazolin-AFT Powder for Injection data sheet 16 February 2023. Medsafe. http://www.medsafe.govt.nz. Accessed 12/04/2023.

Anon. Cefazolin (Pediatric and Neonatal Lexi-Drugs). Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 12/04/2023.

Anon. Cefazolin. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 12/04/2023.

Anon. Cefazolin. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 12/04/2023.

Buckingham R (ed). Cefazolin. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 12/04/2023.

Cefavex 1 g Powder for Injection (Sannovex Pharmaceutical Distributor). MIMS Philippines. http://www.mims.com/philippines. Accessed 12/04/2023.

Cefazolin 1 g Powder for Solution for Injection and Infusion (Noridem Enterprises Ltd.). MHRA. https://products.mhra.gov.uk. Accessed 12/04/2023.

Cefazolin Injection, Powder for Solution (Fresenius Kabi USA, LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 12/04/2023.

Cefazolin Injection, Powder for Solution (Hikma Pharmaceuticals USA Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 12/04/2023.

Cefazolin. Gold Standard Drug Database in ClinicalKey [online]. Elsevier Inc. https://www.clinicalkey.com. Accessed 12/04/2023.

Fazef 1 g Powder for Injection (Zerss Pharmaceutical Pvt. Ltd.). MIMS Philippines. http://www.mims.com/philippines. Accessed 12/04/2023.

Fazlin 1 g Powder for Injection (NCPC Hebei Huamin Pharmaceutical Company Limited). MIMS Philippines. http://www.mims.com/philippines. Accessed 12/04/2023.

Joint Formulary Committee. Cefazolin. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 12/04/2023.

Paediatric Formulary Committee. Cefazolin. BNF for Children [online]. London. BMJ Group, Pharmaceutical Press, and RCPCH Publications. https://www.medicinescomplete.com. Accessed 12/04/2023.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Cefazolin từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2024 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
XEM THÊM
LESS
  • Ajuzolin Inj
  • Alfazole
  • Beecezon
  • Bifazo
  • Biofazolin
  • Cefazolin Actavis
  • Cefazolin Aurobindo
  • Cefazolin Bidiphar
  • Cefazolin Euvipharm
  • Cefazolin JSC Kraspharma
  • Cefazolin Kaifeng
  • Cefazolin Karnataka
  • Cefazolin Meiji
  • Cefazolin Minimed
  • Cefazolin powder for injection
  • Cefazolin Pharbaco
  • Cefazolin Shandong
  • Cefazolin Stada Pymepharco
  • Cefazolin VALENTA
  • Cefazoline Panpharma
  • Cefazolin-Human
  • Cefdivale
  • Codzolin
  • Curazole
  • Greenzolin
  • Harzong
  • Intrazoline
  • Kefzol
  • Lefzomed
  • Linzec
  • LykaLyzolin
  • Novazef
  • Reflin
  • Shinzolin
  • SP. Cefazolin
  • Tafozin
  • Yuhan Cefazolin
  • Zepilen
  • Zoliicef
  • Zolinbac
  • Zolinicef
  • Zolinstad
  • Zolival
  • Zovincef
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in